BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
It was really strange actually that in the patients that were PD-L1 negative, they had the largest benefit, although there was a benefit in both groups. So regardless, the point is that we don't need PD-L1 status to select the patients for treatment for adjuvant pembrolizumab. And in terms of which one I would use, I was using nivolumab for a while.
0
💬
0
Comments
Log in to comment.
There are no comments yet.